(Q38236770)

31 August 2017

title

A safety evaluation of ranibizumab in the treatment of age-related macular degeneration (English)

1 reference

31 August 2017

Jonathan Mark Gibson

1

1 reference

31 August 2017

Stewart James Gibson

series ordinal

2

1 reference

31 August 2017

language of work or name

English

0 references

publication date

5 August 2014

1 reference

Expert Opinion on Drug Safety

31 August 2017

published in

1 reference

31 August 2017

volume

13

1 reference

31 August 2017

issue

9

1 reference

31 August 2017

page(s)

1259-1270

1 reference

Causes of blind and partial sight certifications in England and Wales: April 2007-March 2008.

31 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.939951

Incidence and baseline clinical characteristics of treated neovascular age-related macular degeneration in a well-defined region of the UK.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.939951

Incidence of legal blindness from age-related macular degeneration in denmark: year 2000 to 2010.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.939951

Time trends in the incidence and causes of blindness in Israel

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.939951

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.939951

Pegaptanib for neovascular age-related macular degeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.939951

Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration twelve-week results of an uncontrolled open-label clinical study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.939951

Electrophysiologic and retinal penetration studies following intravitreal injection of bevacizumab (Avastin).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.939951

The International Intravitreal Bevacizumab Safety Survey: using the internet to assess drug safety worldwide

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.939951

A brief history of anti-VEGF for the treatment of ocular angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.939951

Preclinical aspects of anti-VEGF agents for the treatment of wet AMD: ranibizumab and bevacizumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.939951

VEGF-Trap: a VEGF blocker with potent antitumor effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.939951

Safety and efficacy of intravitreal injection of ranibizumab in combination with verteporfin PDT on experimental choroidal neovascularization in the monkey

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.939951

Preclinical pharmacokinetics of Ranibizumab (rhuFabV2) after a single intravitreal administration

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.939951

Biological, preclinical and clinical characteristics of inhibitors of vascular endothelial growth factors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.939951

Intraocular pharmacokinetics of ranibizumab in vitrectomized versus nonvitrectomized eyes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.939951

Long-term follow-up of vascular endothelial growth factor inhibitor therapy for neovascular age-related macular degeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.939951

Seven-year outcomes in ranibizumab-treated patients in ANCHOR, MARINA, and HORIZON: a multicenter cohort study (SEVEN-UP).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.939951

Ranibizumab for neovascular age-related macular degeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.939951

Ranibizumab versus verteporfin for neovascular age-related macular degeneration.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.939951

A variable-dosing regimen with intravitreal ranibizumab for neovascular age-related macular degeneration: year 2 of the PrONTO Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.939951

Management of retinal vascular diseases: a patient-centric approach

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.939951

Intraocular pressure in eyes receiving monthly ranibizumab in 2 pivotal age-related macular degeneration clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.939951

Long-term intraocular pressure changes in patients with neovascular age-related macular degeneration treated with ranibizumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.939951

The SECURE study: long-term safety of ranibizumab 0.5 mg in neovascular age-related macular degeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.939951

Risk of geographic atrophy in the comparison of age-related macular degeneration treatments trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.939951

Pharmacokinetics of ranibizumab in patients with neovascular age-related macular degeneration: a population approach

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.939951

Pharmacokinetics and retinal distribution of ranibizumab, a humanized antibody fragment directed against VEGF-A, following intravitreal administration in rabbits

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.939951

Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.939951

Plasma levels of vascular endothelial growth factor before and after intravitreal injection of bevacizumab, ranibizumab and pegaptanib in patients with age-related macular degeneration, and in patients with diabetic macular oedema

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.939951

Collaborative overview of randomised trials of antiplatelet therapy--I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Antiplatelet Trialists' Collaboration

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.939951

Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: Two-year results of the ANCHOR study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.939951

A Phase IIIb study to evaluate the safety of ranibizumab in subjects with neovascular age-related macular degeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.939951

Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.939951

Safety of ranibizumab in routine clinical practice: 1-year retrospective pooled analysis of four European neovascular AMD registries within the LUMINOUS programme

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.939951

Adverse events with intravitreal injection of vascular endothelial growth factor inhibitors: nested case-control study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.939951

Comparison of outcomes from a phase 3 study of age-related macular degeneration with a matched, observational cohort

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.939951

Peripapillary Neovascular Membrane in a Young Pregnant Woman and Prompt Response to Ranibizumab Injections following Uneventful Delivery.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.939951

Intravitreal bevacizumab injection in unrecognised early pregnancy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.939951

Efficacy of intravitreal bevacizumab for stage 3+ retinopathy of prematurity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.939951

Incidence of hemorrhagic complications after intravitreal bevacizumab (avastin) or ranibizumab (lucentis) injections on systemically anticoagulated patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.939951

Incidence and risk factors for macular hemorrhage following intravitreal ranibizumab injection for neovascular age-related macular degeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.939951

VEGF inhibition, hypertension, and renal toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.939951

Systemic and kidney toxicity of intraocular administration of vascular endothelial growth factor inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.939951

Risks of Mortality, Myocardial Infarction, Bleeding, and Stroke Associated With Therapies for Age-Related Macular Degeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.939951

Ranibizumab and bevacizumab for neovascular age-related macular degeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.939951

Ranibizumab versus bevacizumab to treat neovascular age-related macular degeneration: one-year findings from the IVAN randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.939951

Alternative treatments to inhibit VEGF in age-related choroidal neovascularisation: 2-year findings of the IVAN randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.939951

A safety review and meta-analyses of bevacizumab and ranibizumab: off-label versus goldstandard

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.939951

Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.939951

Intravitreal aflibercept injection for neovascular age-related macular degeneration: ninety-six-week results of the VIEW studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.939951

Safety in Aflibercept versus Ranibizumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.939951

Author reply: To PMID 23084240.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.939951

Ranibizumab combined with verteporfin photodynamic therapy in neovascular age-related macular degeneration: year 1 results of the FOCUS Study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.939951

Stereotactic radiotherapy for neovascular age-related macular degeneration: 52-week safety and efficacy results of the INTREPID study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.939951

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.939951

Intravitreal aflibercept for treatment-resistant neovascular age-related macular degeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.939951

Intravitreal injections: a healthcare failure modes and effects analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.939951

An outbreak of streptococcus endophthalmitis after intravitreal injection of bevacizumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.939951

10.1517/14740338.2014.939951

21 January 2018

Identifiers

DOI

1 reference

31 August 2017

1 reference